Abstract：Objective: To explore the changes in total cholesterol/high density lipoprotein (TC/HDL), apolipoprotein A1 (ApoA1) and lipoprotein (a) [Lp(a)] and their relationship with metabolic syndrome (MS) in patients with schizophrenia. Methods: A total of 93 patients with schizophrenia in the hospital were selected as the study subjects. General data of patients were counted. The levels of serum TC/HDL, ApoA1 and Lp(a) were detected by enzyme-linked immunosorbent assay, and the patients were divided into MS group (n=32) and non-MS group (n=61) according to whether they were complicated with MS. The general data and levels of serum TC/HDL, ApoA1 and Lp(a) were compared between the two groups. Multivariate Logistic regression analysis was used to analyze the risk factors of MS in patients with schizophrenia. Results: The BMI, SBP, DBP, FPG, serum TG and LDL-C in MS group were significantly higher than those in non-MS group (P<0.05) while the level of HDL-C was significantly lower than that in non-MS group (P<0.05). There were no statistically significant differences in gender, age, course of disease, smoking history, drinking history, antipsychotic drug use, serum TC level, and PANSS score between the two groups (P>0.05). TC/HDL and Lp(a) in MS group were significantly higher than those in non-MS group (P<0.05) while ApoA1 was significantly lower than that in non-MS group (P<0.05). Multivariate Logistic regression analysis showed that BMI, FPG, serum TG, LDL-C, Lp(a) and TC/HDL were risk factors affecting MS in patients with schizophrenia, and serum ApoA1 was a protective factor (P<0.05). Conclusion: Serum TC/HDL, ApoA1 and Lp (a) levels are the influencing factors of MS in patients with schizophrenia, and the increases of TC/HDL and Lp (a) and the decrease of ApoA1 can increase the risk of MS in patients.
鲁文, 龚陈, 向文, 赵云飞, 李承美. 精神分裂症患者TC/HDL ApoA1 Lp(a)水平变化及与代谢综合征的关系分析[J]. 河北医学, 2023, 29(9): 1564-1568.
LU Wen, GONG Chen, XIANG Wen, et al. Changes in TC/HDL, ApoA1 and Lp(a) Levels in Patients with Schizophrenia and Their Relationship with Metabolic Syndrome. HeBei Med, 2023, 29(9): 1564-1568.
2023, Vol. 29 
冀公网安备13080202000677号